Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
Completed · Phase 3 · NCT03569293
Conditions: Atopic Dermatitis
At a glance
- Research payments reported, 2025
- $43,376
- U.S. investigators named
- 15
- Sites paid
- 15
- Planned or actual enrollment
- 912
About the trial
- Sponsor
- AbbVie
- Tested
- Placebo for Upadacitinib (drug), Upadacitinib (drug)
- Dates
- Started 2018-08-13; completion 2025-10-10
- Results posted
- Yes
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
From ClinicalTrials.gov, last updated 2026-06-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $43,376 in research payments for this study in 2025 (31 payments).
Products named: Rinvoq
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Warner W. Carr, MD Allergy & Immunology · Laguna Niguel, CA
- Albert Chiou, MD Dermatology · Stanford, CA
- Vivian Laquer, M.D. Dermatology · Irvine, CA
- Ricardo A. Tan, MD Allergy & Immunology · Los Angeles, CA
- Matthew B. Zook, MD, PHD Dermatology · St Petersburg, FL
- Holly E. Kanavy, D.O. Dermatology · Bronx, NY
- Benjamin D. Ehst, M.D., PH.D. Dermatology · Portland, OR
- Eric L. Simpson, MD Dermatology · Portland, OR
- Alma M. Cruz Santana, MD Dermatology · Carolina, PR
- Maria I. Martinez Colon, M.D. Dermatology · San Juan, PR
- Kathleen P. Gordon, DO Internal Medicine · Johnston, RI
- Jennifer C. Cather, M.D. Dermatology · Dallas, TX
- William C. Howland III, MD Allergy & Immunology · Austin, TX
- Patricia C. Lee, M.D. Dermatology · Webster, TX
- Angela Y. Moore, MD, PA Dermatopathology · Arlington, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ohsu Hospital and Clinics, OR $9,522
- The Board of Trustees of the Leland Stanford Junior University $9,249
- Biomedical Research Alliance of New York $5,740
- Allergy & Asthma Associates Of $4,959
- Grupo Dermatologico Carolina $3,092
- Arlington Research Center Inc $2,085
- First Oc Dermatolgy Research Inc $2,000
- Clinical Research Puerto Rico $1,701
- Howland Allergy & Asthma PLLC $1,688
- Modern Research Associates PLLC $1,636
- Ricardo Antonio Tan MD Inc $489
- Oregon Med Research Ctr PC $455
- Clinical PArtners LLC $442
- Center for Clinical Studies LTD LLP $231
- Academic Alliance in Dermatology $90
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.